Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer

BACKGROUND: Neoadjuvant immunotherapy with anti-PD-1 was proved promising in resectable non-small cell lung cancer (NSCLC). Immune-related adverse events (irAEs) have been preliminarily implicated their association with treatment efficacy. Here we elucidated the early onset of irAEs associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Ye, Li, Xiang, Liu, Bing, Wang, Jia, Lv, Chao, Li, Shaolei, Wang, Yuzhao, Chen, Jinfeng, Yan, Shi, Wu, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225556/
https://www.ncbi.nlm.nih.gov/pubmed/37256186
http://dx.doi.org/10.3389/fonc.2023.1135140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225556/
https://www.ncbi.nlm.nih.gov/pubmed/37256186
http://dx.doi.org/10.3389/fonc.2023.1135140

Ejemplares similares